Roche Drug Candidate Works in Type of Lung Cancer in Need of New Therapies

Dow Jones07-02

0625 GMT - Roche Holding's latest study results show an experimental drug worked in a type of lung cancer for which new treatments are needed, Vontobel's Stefan Schneider says in a research note. The late-stage study tested Roche's divarasib drug candidate against other approved medications for a specific mutation of lung cancer and showed the product developed by the Swiss drugmaker led to meaningful improvements, the analyst says. "Efficacious treatments for this type of lung cancer represent a significant unmet need in lung cancer care," he adds. Vontobel estimates divarasib could generate 600 million Swiss francs in sales at its peak, and increases the probability that this forecast is hit to 80% from 40% previously. As a result, Vontobel lifts its target price on Roche stock to 348 francs from 346 francs. Roche shares closed at 328.80 francs Wednesday. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 02, 2026 02:25 ET (06:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648257452?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 14:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648257452","market":"nz","top_or_hot":-1,"title":"Roche Drug Candidate Works in Type of Lung Cancer in Need of New Therapies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0625 GMT - Roche Holding's latest study results show an experimental drug worked in a type of lung cancer for which new treatments are needed, Vontobel's Stefan Schneider says in a research note. The late-stage study tested Roche's divarasib drug candidate against other approved medications for a specific mutation of lung cancer and showed the product developed by the Swiss drugmaker led to meaningful improvements, the analyst says. \"Efficacious treatments for this type of lung cancer represent a significant unmet need in lung cancer care,\" he adds. Vontobel estimates divarasib could generate 600 million Swiss francs in sales at its peak, and increases the probability that this forecast is hit to 80% from 40% previously. As a result, Vontobel lifts its target price on Roche stock to 348 francs from 346 francs. Roche shares closed at 328.80 francs Wednesday. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 02, 2026 02:25 ET (06:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Drug Candidate Works in Type of Lung Cancer in Need of New Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Drug Candidate Works in Type of Lung Cancer in Need of New Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-02 14:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0625 GMT - Roche Holding's latest study results show an experimental drug worked in a type of lung cancer for which new treatments are needed, Vontobel's Stefan Schneider says in a research note. The late-stage study tested Roche's divarasib drug candidate against other approved medications for a specific mutation of lung cancer and showed the product developed by the Swiss drugmaker led to meaningful improvements, the analyst says. \"Efficacious treatments for this type of lung cancer represent a significant unmet need in lung cancer care,\" he adds. Vontobel estimates divarasib could generate 600 million Swiss francs in sales at its peak, and increases the probability that this forecast is hit to 80% from 40% previously. As a result, Vontobel lifts its target price on Roche stock to 348 francs from 346 francs. Roche shares closed at 328.80 francs Wednesday. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 02, 2026 02:25 ET (06:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RHHBY","symbol_name":"罗氏控股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2648257452","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648257452","pubTimestamp":1782973500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0625 GMT - Roche Holding's latest study results show an experimental drug worked in a type of lung cancer for which new treatments are needed, Vontobel's Stefan Schneider says in a research note. The late-stage study tested Roche's divarasib drug candidate against other approved medications for a specific mutation of lung cancer and showed the product developed by the Swiss drugmaker led to meaningful improvements, the analyst says. \"Efficacious treatments for this type of lung cancer represent a significant unmet need in lung cancer care,\" he adds. Vontobel estimates divarasib could generate 600 million Swiss francs in sales at its peak, and increases the probability that this forecast is hit to 80% from 40% previously. As a result, Vontobel lifts its target price on Roche stock to 348 francs from 346 francs. Roche shares closed at 328.80 francs Wednesday.  Dow Jones NewswiresJuly 02, 2026 02:25 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RHHBY":"罗氏控股","03165":"华夏欧优股对冲","BK4007":"制药"},"translate_title":"罗氏候选药物治疗需要新疗法的肺癌类型","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":0.9,"03165":0.6},"content_text":"0625 GMT - Roche Holding's latest study results show an experimental drug worked in a type of lung cancer for which new treatments are needed, Vontobel's Stefan Schneider says in a research note. The late-stage study tested Roche's divarasib drug candidate against other approved medications for a specific mutation of lung cancer and showed the product developed by the Swiss drugmaker led to meaningful improvements, the analyst says. \"Efficacious treatments for this type of lung cancer represent a significant unmet need in lung cancer care,\" he adds. Vontobel estimates divarasib could generate 600 million Swiss francs in sales at its peak, and increases the probability that this forecast is hit to 80% from 40% previously. As a result, Vontobel lifts its target price on Roche stock to 348 francs from 346 francs. Roche shares closed at 328.80 francs Wednesday. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 02, 2026 02:25 ET (06:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648257452","isCrawlerRequest":true}